Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859393 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL3920174 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL6576494 | 0.89 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL6579051 | 0.89 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL6576487 | 0.89 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL3926773 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNASMN1; SMN2CHRNA7 | |
| SCHEMBL28754175 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNASMN1; SMN2CHRNA7 | |
| SCHEMBL315436 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNASMN1; SMN2CHRNA7 | |
| SCHEMBL540784 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 | |
| SCHEMBL3176056 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNASMN1; SMN2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192295-A | Arylpropylamine derivative and application thereof | 江苏恩华药业股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-1706385-B1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1934159-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| EP-1505156-B1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | CONSORTIUM ELEKTROCHEM IND (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2005-02-10 | — | — | US | disclosed |
| EP-1505156-A1 | Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester | Consortium für elektrochemische Industrie GmbH (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6395739-B1 | CARDIOVASCUALR DISORDERS; HYPOTENSIVE AGENTS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-0753511-B1 | 4-INDOL-1-YL BUTYRIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ALPHA1-ADRENERGIC RECEPTORS AND TESTOSTERONE 5ALPHA-REDUCTASES | ZERIA PHARM CO LTD (JP) | 2001-07-11 | — | — | EP | disclosed |
| EP-1090913-A1 | N-PHENYL-N'-PHENYLPROPYLPIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
| US-5760040-A | THERAPEUTIC AGENT FOR PROSTATIC HYPERTROPHY, URINATION DISORDER, ALOPECIA AND ACNE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0753511-A1 | INDOLE DERIVATIVE AND MEDICINE CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | ALDH1A1 76/4885MAPT 3024/4885LMNA 3099/4885 |
| US-20050032182-A1 | Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters | LIPC, LIPE, LIPA | ALDH1A1 187/4885MAPT 4496/4885LMNA 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.